Bioavailability and Pharmacokinetics Study of FDL169 in Healthy Subjects and Subjects With Cystic Fibrosis

F

Flatley Discovery Lab LLC

Status and phase

Completed
Phase 2
Phase 1

Conditions

Cystic Fibrosis

Treatments

Drug: FDL169

Study type

Interventional

Funder types

Other

Identifiers

NCT02767297
FDL169-2015-03

Details and patient eligibility

About

To determine the relative bioavailability of the capsule (reference) and tablet (test) formulations of FDL169 in healthy adult males and females, and to evaluate the pharmacokinetic (PK) profile FDL169 tablets (test formulation) in both healthy adult males and females, and subjects with cystic fibrosis (CF).

Full description

This is a three-part study. Part 1: Part 1 of the study is a single dose, open-label, randomized crossover study in healthy male and female subjects to compare the relative bioavailability of two formulations of FDL169. Part 2: Part 2 of the study is a multiple, escalating dose study of three different doses of the test formulation of FDL169 in healthy male and female subjects to evaluate the PK profile of the test formulation of FDL169. Part 3: Part 3 of the study is a single dose, open-label study in male and female subjects with CF to determine the PK profile of the test formulation of FDL169.

Enrollment

46 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Parts 1 and 2:

  • Healthy, males and females between 18 and 55 years of age, inclusive, with a BMI of >19 and <30 kg/m2.
  • If sexually active, must meet the contraception requirements.

Part 3:

  • Male and female subjects aged 18 years and older.
  • If sexually active, must meet the contraception requirements.
  • Diagnosis of CF.
  • History of pancreatic insufficiency.
  • Forced expiratory volume in 1 second (FEV1) ≥40% of predicted normal for age, sex and height at screening.

Exclusion criteria

Parts 1 and 2:

  • Prior or ongoing medical condition, medical history, physical findings, ECG findings or laboratory abnormality that could adversely affect the safety of the subject.
  • Alkaline phosphatase, aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) level >1.5 x upper limit of normal (ULN) at screening.
  • Use of prescription or non-prescription drugs within 21 days or five half-lives (whichever is longer) before the first dose of study medication, unless the medication will not interfere with the study procedures or compromise subject safety.
  • Pregnant or nursing females.
  • Serum creatinine or total bilirubin >1.5 x ULN (isolated bilirubin >1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin is <35%).
  • History of prolonged QT and/or QTcF interval.
  • ECG with a single QTcF >450 msec in males, >460 msec in females, at Screening.
  • Positive urinary drugs of abuse screen at Screening or Day -1, or positive alcohol screen at Day -1.
  • History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >21 units.
  • History of human immunodeficiency virus (HIV) or positive HIV, hepatitis B or hepatitis C results at screening.
  • Donation of 500 mL or more blood within 3 months before Day -1.
  • Participation in a clinical trial involving receipt of an investigational product within the past 90 days or exposure to more than four new chemical entities with 12 months of the first dosing day.
  • Current smoking or use of tobacco products or substitutes. Former smokers will be eligible, provided they have not smoked for at least 6 months before Day -1.
  • Use of any prescription and non-prescription medications that are inhibitors or inducers of cytochrome P450 (CYP) 3A4 within 7 days before Day -1.

Part 3:

  • History of any illness, or ongoing acute illness that could impact the safety of the subject or confound study results.
  • Abnormal liver function ≥3 x ULN: AST, ALT, total bilirubin.
  • A pulmonary exacerbation, or changes in therapy for pulmonary disease within 4 weeks prior to the Baseline (Day 1) Visit
  • Use of herbal and dietary supplements within 21 days or five half-lives (whichever is longer) before the first dose of study medication, unless the medication will not interfere with the study procedures or compromise subject safety.
  • Pregnant or nursing females.
  • Serum creatinine or total bilirubin >1.5 x ULN (isolated bilirubin >1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin is <35%).
  • History of prolonged QT and/or QTcF interval.
  • ECG with a single QTcF >450 msec in males, >460 msec in females, at Screening.
  • Positive urinary drugs of abuse screen at Screening or Day -1, or positive alcohol screen at Day -1.
  • History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >21 units.
  • History of HIV, or positive HIV, hepatitis B or hepatitis C results at screening.
  • Donation of 500 mL or more blood within 3 months before Day -1.
  • Participation in a clinical trial involving receipt of an investigational product within the past 90 days or exposure to more than four new chemical entities with 12 months of the first dosing day.
  • Current smoking or use of tobacco products or substitutes. Former smokers will be eligible, provided they have not smoked for at least 6 months before Day -1.
  • Use of any prescription and non-prescription medications that are inhibitors or inducers of CYP3A4, within 7 days before Day -1.

Trial design

46 participants in 5 patient groups

Part 1: Single dose (cross over)
Experimental group
Description:
FDL169 reference formulation and test formulation administered as a single dose in healthy subjects
Treatment:
Drug: FDL169
Part 2: Multiple dose (dose level 1)
Experimental group
Description:
FDL169 test formulation (Dose level 1) administered as repeat doses in healthy subjects
Treatment:
Drug: FDL169
Part 2: Multiple dose (dose level 2)
Experimental group
Description:
FDL169 test formulation (Dose level 2) administered as repeat doses in healthy subjects
Treatment:
Drug: FDL169
Part 2: Multiple dose (dose level 3)
Experimental group
Description:
FDL169 test formulation (Dose level 3) administered as repeat doses in healthy subjects
Treatment:
Drug: FDL169
Part 3: Single dose
Experimental group
Description:
FDL169 test formulation administered as a single dose in CF subjects
Treatment:
Drug: FDL169

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems